{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:52:32Z","timestamp":1792723952250,"version":"4.5.0"},"reference-count":38,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Two fixed-dose combination triple therapies, budesonide\/glycopyrronium\/formoterol fumarate dihydrate (BGF) 320\/14.4\/10\u00a0\u03bcg and fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) 100\/62.5\/25\u00a0\u03bcg, have been shown to reduce all-cause mortality in phase III trials. A recent matching-adjusted indirect comparison showed greater mortality reduction with BGF versus FF\/UMEC\/VI. However, the comparative cost-effectiveness of these treatments remains unknown. This study aimed to use a cost-effectiveness model to compare BGF with FF\/UMEC\/VI in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) who are eligible for triple therapy from a UK third-party payer perspective.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A cohort-based semi-Markov model was used with the natural progression of COPD defined by four lung function levels. Input parameters included participant characteristics and clinical efficacy parameters derived from the ETHOS and KRONOS trials, the UK general population and published literature. Unit costs were obtained from the UK National Health System Schedule of Reference Costs (2021\/2022), the Personal Social Services Research Unit (2022) and published literature. Outputs included an incremental cost-effectiveness ratio, costs, quality-adjusted life years and life years at time horizons of 1 and 5\u00a0years. Model inputs and assumptions were subject to deterministic and probabilistic sensitivity and scenario analyses.\n                    <jats:bold>Results:<\/jats:bold>\n                    At both 1- and 5-year time horizons, BGF was less costly (-\u00a37.24 and -\u00a323.03 per patient) and more effective (0.002 and 0.21 quality-adjusted life years per patient) versus FF\/UMEC\/VI, respectively. Due to a reduced mortality rate, more patients remained on BGF treatment than on FF\/UMEC\/VI, which induced higher treatment-related costs; however, the latter was offset by decreased end-of-life costs, as BGF avoided more deaths.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    BGF may improve health outcomes and reduce healthcare costs compared with FF\/UMEC\/VI in patients with moderate-to-very severe COPD in a UK setting.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0111","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T10:46:53Z","timestamp":1765795613000},"source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease"],"prefix":"10.57264","volume":"15","author":[{"given":"Krishnali","family":"Parsekar","sequence":"first","affiliation":[{"name":"Health Economics &amp; Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhram","family":"Pandey","sequence":"additional","affiliation":[{"name":"Pharmacoevidence Private Limited, Mohali, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Tansey-Dwyer","sequence":"additional","affiliation":[{"name":"Global Market Access &amp; Pricing, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Marshall","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Rustignoli","sequence":"additional","affiliation":[{"name":"Market Access, BioPharmaceuticals Medical, AstraZeneca, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pollack","sequence":"additional","affiliation":[{"name":"Respiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Pharmacoevidence Private Limited, Mohali, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ouwens","sequence":"additional","affiliation":[{"name":"Real World Science &amp; Analytics, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"11","key":"e_1_3_9_2_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision","volume":"206","author":"Celli B","year":"2022","unstructured":"Celli B, Fabbri L, Criner G Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am. J. Respir. Crit. Care Med. 206(11), 1317\u20131325 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12890-016-0238-9","article-title":"Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities","volume":"16","author":"Wacker ME","year":"2016","unstructured":"Wacker ME, Jorres RA, Karch A Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm. Med. 16(1), 70 (2016).","journal-title":"BMC Pulm. Med."},{"key":"e_1_3_9_4_2","unstructured":"World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD). (Accessed: 12 October 2023). Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd)"},{"issue":"5","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/15412555.2010.510160","article-title":"Mortality in COPD: causes, risk factors, and prevention","volume":"7","author":"Berry CE","year":"2010","unstructured":"Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD 7(5), 375\u2013382 (2010).","journal-title":"COPD"},{"issue":"5","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/thx.2006.072348","article-title":"Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee","volume":"62","author":"McGarvey LP","year":"2007","unstructured":"McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax 62(5), 411\u2013415 (2007).","journal-title":"Thorax"},{"issue":"1","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki KM","year":"2018","unstructured":"Kunisaki KM, Dransfield MT, Anderson JA Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am. J. Respir. Crit. Care Med. 198(1), 51\u201357 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa S","year":"2012","unstructured":"Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 67(11), 957\u2013963 (2012).","journal-title":"Thorax"},{"issue":"8","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/thorax-2022-219039","article-title":"Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent postdiagnosis COPD exacerbations and mortality: EXACOS-UK health care data study","volume":"78","author":"Whittaker H","year":"2023","unstructured":"Whittaker H, Nordon C, Rubino A Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent postdiagnosis COPD exacerbations and mortality: EXACOS-UK health care data study. Thorax 78(8), 760\u2013766 (2023).","journal-title":"Thorax"},{"issue":"8","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"e1183","DOI":"10.1016\/S2214-109X(23)00217-6","article-title":"The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study","volume":"11","author":"Chen S","year":"2023","unstructured":"Chen S, Kuhn M, Prettner K The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. Lancet Glob. Health 11(8), e1183\u2013e1193 (2023).","journal-title":"Lancet Glob. Health"},{"issue":"1","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12931-019-1179-7","article-title":"Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study","volume":"20","author":"Kirsch F","year":"2019","unstructured":"Kirsch F, Schramm A, Schwarzkopf L Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study. Respir. Res. 20(1), 215 (2019).","journal-title":"Respir. Res."},{"issue":"6","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1007\/s12325-021-01703-z","article-title":"Efficacy and safety of budesonide\/glycopyrronium\/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta-analysis","volume":"38","author":"Bourdin A","year":"2021","unstructured":"Bourdin A, Molinari N, Ferguson GT Efficacy and safety of budesonide\/glycopyrronium\/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta-analysis. Adv. Ther. 38(6), 3089\u20133112 (2021).","journal-title":"Adv. Ther."},{"key":"e_1_3_9_13_2","unstructured":"NHS England. Respiratory disease. (Accessed: 9 October 2024). Available at: https:\/\/www.england.nhs.uk\/ourwork\/clinical-policy\/respiratory-disease\/#:\u223c:text=The%20annual%20economic%20burden%20of the%20UK%20%C2%A311billion%20annually"},{"key":"e_1_3_9_14_2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2024 GOLD report. (Accessed: 7 May 2024). Available at: https:\/\/goldcopd.org\/2024-gold-report\/"},{"issue":"5","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chest.2023.11.040","article-title":"National and local direct medical cost burden of COPD in the United States from 2016 to 2019 and projections through 2029","volume":"165","author":"Mannino DM","year":"2024","unstructured":"Mannino DM, Roberts MH, Mapel DW National and local direct medical cost burden of COPD in the United States from 2016 to 2019 and projections through 2029. Chest 165(5), 1093\u20131106 (2024).","journal-title":"Chest"},{"issue":"5","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for COPD: a randomized, double-blind, multi-center parallel-group study","volume":"203","author":"Martinez FJ","year":"2020","unstructured":"Martinez FJ, Rabe KF, Ferguson GT Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for COPD: a randomized, double-blind, multi-center parallel-group study. Am. J. Respir. Crit. Care Med. 203(5), 553\u2013564 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson DA","year":"2020","unstructured":"Lipson DA, Crim C, Criner GJ Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 201(12), 1508\u20131516 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/03007995.2023.2247969","article-title":"Mortality risk reduction with budesonide\/glycopyrrolate\/formoterol fumarate versus fluticasone furoate\/umeclidinium\/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT","volume":"39","author":"Stolz D","year":"2023","unstructured":"Stolz D, Hermansson E, Ouwens M Mortality risk reduction with budesonide\/glycopyrrolate\/formoterol fumarate versus fluticasone furoate\/umeclidinium\/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT. Curr. Med. Res. Opin. 39(10), 1395\u20131405 (2023).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.rmed.2019.08.010","article-title":"A Phase III study of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler 320\/18\/9.6 ug and 160\/18\/9.6 ug using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol","volume":"158","author":"Rabe KF","year":"2019","unstructured":"Rabe KF, Martinez FJ, Ferguson GT A Phase III study of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler 320\/18\/9.6 ug and 160\/18\/9.6 ug using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol. Respir. Med. 158, 59\u201366 (2019).","journal-title":"Respir. Med."},{"issue":"10","key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","article-title":"Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase III randomised controlled trial","volume":"6","author":"Ferguson GT","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase III randomised controlled trial. Lancet Respir. Med. 6(10), 747\u2013758 (2018).","journal-title":"Lancet Respir. Med."},{"key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.2147\/COPD.S366765","article-title":"Cost-effectiveness of once-daily single-inhaler COPD triple therapy in Spain: IMPACT trial","volume":"17","author":"Paly VF","year":"2022","unstructured":"Paly VF, Vallejo-Aparicio LA, Martin A Cost-effectiveness of once-daily single-inhaler COPD triple therapy in Spain: IMPACT trial. Int. J. Chron. Obstruct. Pulmon. Dis. 17, 3097\u20133109 (2022).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_3_9_22_2","unstructured":"National Institute for Health and Care Excellence. Overview: NICE health technology evaluations: the manual: guidance. (Accessed: 7 May 2024). Available at: https:\/\/www.nice.org.uk\/process\/pmg36"},{"key":"e_1_3_9_23_2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis management and prevention. (Accessed: 7 May 2024). Available at: https:\/\/goldcopd.org\/2023-gold-report-2\/"},{"key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/COPD.S381138","article-title":"Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate dihydrate versus dual therapies in moderate-to-very severe chronic obstructive pulmonary disease: United Kingdom analysis using the ETHOS study","volume":"17","author":"de Nigris E","year":"2022","unstructured":"de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J. Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate dihydrate versus dual therapies in moderate-to-very severe chronic obstructive pulmonary disease: United Kingdom analysis using the ETHOS study. Int. J. Chron. Obstruct. Pulmon. Dis. 17, 2987\u20133000 (2022).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/COPD.S286087","article-title":"Budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler improves exacerbation outcomes in patients with COPD without a recent exacerbation history: a subgroup analysis of KRONOS","volume":"16","author":"Martinez FJ","year":"2021","unstructured":"Martinez FJ, Ferguson GT, Bourne E Budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler improves exacerbation outcomes in patients with COPD without a recent exacerbation history: a subgroup analysis of KRONOS. Int. J. Chron. Obstruct. Pulmon. Dis. 16, 179\u2013189 (2021).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_3_9_26_2","unstructured":"Office of National Statistics. National life tables. UK 2016\u20132018 2019. (Accessed: 7 May 2024). Available at: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables"},{"key":"e_1_3_9_27_2","volume-title":"International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Annual Meeting","author":"Pandey S","year":"2024","unstructured":"Pandey S, Parsekar K, Singh B Decomposing overall mortality into latent disease-specific health states mortality to inform cost-effectiveness modelling. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Annual Meeting. Barcelona, Spain (2024)."},{"issue":"1","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10198-013-0456-5","article-title":"Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom","volume":"15","author":"Samyshkin Y","year":"2014","unstructured":"Samyshkin Y, Kotchie RW, Mork AC, Briggs AH, Bateman ED. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur. J. Health Econ. 15(1), 69\u201382 (2014).","journal-title":"Eur. J. Health Econ."},{"issue":"4","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0272989X16653118","article-title":"Development of the galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model","volume":"37","author":"Briggs AH","year":"2017","unstructured":"Briggs AH, Baker T, Risebrough NA Development of the galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med. Decis. Making 37(4), 469\u2013480 (2017).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_9_30_2","article-title":"Healthcare trajectories and costs in the last year of life: a retrospective primary care and hospital analysis","author":"Luta X","year":"2020","unstructured":"Luta X, Diernberger K, Bowden J Healthcare trajectories and costs in the last year of life: a retrospective primary care and hospital analysis. BMJ Support. Palliat. Care doi: 10.1136\/bmjspcare-2020-002630 (2020).","journal-title":"BMJ Support. Palliat. Care"},{"key":"e_1_3_9_31_2","unstructured":"NHS England. Reference cost collection: national schedule of reference costs 2017-18 - NHS trusts and NHS Foundation trusts. (Accessed: 10 July 2024). Available at: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/"},{"key":"e_1_3_9_32_2","unstructured":"Personal Social Services Research Unit. Unit costs of health and social care 2022. (Accessed: 10 July 2024). Available at: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/"},{"key":"e_1_3_9_33_2","unstructured":"British National Formulary. Pharmaceuticals prices 2018."},{"key":"e_1_3_9_34_2","unstructured":"NICE. The guidelines manual. (Accessed: 30 June 2024). Available at: https:\/\/www.nice.org.uk\/process\/pmg6"},{"issue":"4","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/11589270-000000000-00000","article-title":"Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues","volume":"30","author":"Rutten-van Molken MP","year":"2012","unstructured":"Rutten-van Molken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics 30(4), 271\u2013302 (2012).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/COPD.S5237","article-title":"Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III follow-up study","volume":"4","author":"Shavelle RM","year":"2009","unstructured":"Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III follow-up study. Int. J. Chron. Obstruct. Pulmon. Dis. 4, 137\u2013148 (2009).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_3_9_37_2","unstructured":"NICE. National Institute for Health and Care Excellence single technology appraisal \u2013 roflumilast for treating chronic obstructive pulmonary disease [ID984]. (2017). (Accessed: 7 May 2024). Available at: https:\/\/www.nice.org.uk\/guidance\/ta461"},{"key":"e_1_3_9_38_2","volume-title":"National Supplementary Report","author":"Stone RA","year":"2017","unstructured":"Stone RA, Holzhauer-Barrie J, Lowe D COPD: who cares when it matters most? National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: outcomes from the clinical audit of COPD exacerbations admitted to acute hospitals in England 2014. National Supplementary Report. Royal Colleage of Physicians, UK (2017)."},{"key":"e_1_3_9_39_2","volume-title":"National Clinical Audit Report","author":"Stone RA","year":"2015","unstructured":"Stone RA, Holzhauer-Barrie J, Lowe D COPD: who cares matters. National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: clinical audit of COPD exacerbations admitted to acute units in England and Wales 2014. National Clinical Audit Report. Royal Colleage of Physicians, UK (2015)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:30:48Z","timestamp":1765884648000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.57264\/cer-2025-0111"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0111","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e250111"}}